Efficacy of Prolotherapy for Osteoarthritis: A Systematic Review
DOI:
https://doi.org/10.2340/jrm.v55.2572Keywords:
dextrose prolotherapy, osteoarthritis, evidencebased medicine, systematic reviewAbstract
Objective: Current treatments for osteoarthritis do not resolve the underlying cause. Dextrose prolotherapy is an alternative method that has been proposed for treatment of osteoarthritis, due to its ability to aid tissue regeneration, improve clinical manifestations, and repair damaged tissue structures, which are pathological conditions in osteoarthritis. The aim of this systematic review was to evaluate the efficacy of dextrose prolotherapy compared with other interventions in the management of osteoarthritis.
Methods: Electronic databases PubMed, Google Scholar, Cochrane, and BioMed Central were searched from inception to October 2021. Search terms included [(prolotherapy) OR (prolotherapies) OR (dextrose prolotherapy)] AND [(osteoarthritis) OR (osteoarthritides) OR (knee osteoarthritis) OR (hip osteoarthritis) OR (hand osteoarthritis) OR (shoulder osteoarthritis)]. Randomized controlled trials that compared the use of dextrose prolotherapy with other interventions (injection, placebo, therapy, or conservative treatment) in the treatment of osteoarthritis were included. Potential articles were screened for eligibility, and data were extracted by all authors. Risk of bias was assessed using the Cochrane Risk of Bias tool. Study population, methods, and results data were extracted and tabulated by 3 authors.
Results: 12 studies reported that DPT was as effective or even more effective in improving functional outcomes compared with other interventions whilst others found that HA, PRP, EP, and ACS were more effective. 14 studies assessed the effectiveness of DPT and ten of them reported that DPT was more effective in reducing pain compared with other interventions.
Conclusion: Dextrose prolotherapy in osteoarthritis confers potential benefits for pain and functional outcomes, but this systematic review found that the studies to date are at high risk of bias.
LAY ABSTRACT
Osteoarthritis is a long-term chronic illness defined by the degeneration of cartilage in joints, causing bones to rub together and causing stiffness, discomfort, and decreased movement. Current treatment options for osteoarthritis do not address the fundamental cause. Dextrose prolotherapy is a potential alternative approach for OA, due to its capacity to help tissue regeneration, improve clinical symptoms, and repair damaged tissue structures, which are pathogenic in osteoarthritis. Despite several comparison studies, the superiority of dextrose prolotherapy in osteoarthritis remains equivocal due to contradictory outcomes. Based on this review, dextrose prolotherapy should be considered as a possible treatment for osteoarthritis.
Downloads
References
World Health Organization (WHO). Essential medicines and health products - priority diseases and reasons for inclusion - osteoarthritis. Geneva: WHO; 2013; 12: 6-8.
Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol 2020; 72: 220-233.
https://doi.org/10.1002/art.41142 DOI: https://doi.org/10.1002/art.41142
Rahimzadeh P, Imani F, Faiz SHR, Entezary SR, Zamanabadi MN, Alebouyeh MR. The effects of injecting intra-articular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis. Clin Interv Aging 2018; 13: 73-79.
https://doi.org/10.2147/CIA.S147757 DOI: https://doi.org/10.2147/CIA.S147757
Linetsky FS, Manchikanti L. Regenerative injection therapy for axial pain. Tech Reg Anesth Pain Manag 2005; 9: 40-49.
https://doi.org/10.1053/j.trap.2005.01.004 DOI: https://doi.org/10.1053/j.trap.2005.01.004
Goswami A. Prolotherapy. J Pain Palliat Care Pharmacother 2012; 26: 376-378.
https://doi.org/10.3109/15360288.2012.734900 DOI: https://doi.org/10.3109/15360288.2012.734900
Distel LM, Best TM. Prolotherapy: a clinical review of its role in treating chronic musculoskeletal pain. PM&R 2011; 3: S78-S81.
https://doi.org/10.1016/j.pmrj.2011.04.003
DeChellis DM, Cortazzo MH. Regenerative medicine in the field of pain medicine: prolotherapy, platelet-rich plasma therapy, and stem cell therapy - theory and evidence. Tech Reg Anesth Pain Manag 2011; 15: 74-80.
https://doi.org/10.1053/j.trap.2011.05.002 DOI: https://doi.org/10.1053/j.trap.2011.05.002
Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928-d5928.
https://doi.org/10.1136/bmj.d5928 DOI: https://doi.org/10.1136/bmj.d5928
Hashemi M, Jalili P, Mennati S, Koosha A, Rohanifar R, Madadi F, et al. The effects of prolotherapy with hypertonic dextrose versus prolozone (intraarticular ozone) in patients with knee osteoarthritis. Anesthesiol Pain Med 2015; 5: 5-8.
https://doi.org/10.5812/aapm.27585 DOI: https://doi.org/10.5812/aapm.27585
Rabago D, Patterson JJ, Mundt M, Kijowski R, Grettie J, Segal NA, et al. Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. Ann Fam Med 2013; 11: 229-237.
https://doi.org/10.1370/afm.1504 DOI: https://doi.org/10.1370/afm.1504
Sert AT, Sen EI, Esmaeilzadeh S, Ozcan E. The effects of dextrose prolotherapy in symptomatic knee osteoarthritis: a randomized controlled study. J Altern Complement Med 2020; 26: 409-417.
https://doi.org/10.1089/acm.2019.0335 DOI: https://doi.org/10.1089/acm.2019.0335
Pishgahi A, Abolhasan R, Shakouri SK, Zangbar MSS, Dareshiri S, Kiyakalayeh SR, et al. Effect of dextrose prolotherapy, platelet rich plasma and autologous conditioned serum on knee osteoarthritis: a randomized clinical trial. Iran J Allergy, Asthma Immunol 2020; 19: 243-252.
https://doi.org/10.18502/ijaai.v19i3.3452 DOI: https://doi.org/10.18502/ijaai.v19i3.3452
Waluyo Y, Budu, Bukhari A, Adnan E, Haryadi RD, Idris I, et al. Changes in levels of cartilage oligomeric proteinase and urinary C-terminal telopeptide of type II collagen in subjects with knee osteoarthritis after dextrose prolotherapy: a randomized controlled trial. J Rehabil Med 2021; 53: jrm00196.
https://doi.org/10.2340/16501977-2835 DOI: https://doi.org/10.2340/16501977-2835
Hosseini B, Taheri M, Ardekani RP, Moradi S, Mofrad MK. Periarticular hypertonic dextrose vs intraarticular hyaluronic acid injections: a comparison of two minimally invasive techniques in the treatment of symptomatic knee osteoarthritis. Open Access Rheumatol Res Rev 2019; 11: 269-274.
https://doi.org/10.2147/OARRR.S215576 DOI: https://doi.org/10.2147/OARRR.S215576
Gül D, Orsçelik A, Akpancar S. Treatment of osteoarthritis secondary to developmental dysplasia of the hip with prolotherapy injection versus a supervised progressive exercise control. Med Sci Monit 2020; 26: 1-8.
https://doi.org/10.12659/MSM.919166 DOI: https://doi.org/10.12659/MSM.919166
Rezasoltani Z, Azizi S, Najafi S, Sanati E, Dadarkhah A, Abdorrazaghi F. Physical therapy, intra-articular dextrose prolotherapy, botulinum neurotoxin, and hyaluronic acid for knee osteoarthritis: randomized clinical trial. Int J Rehabil Res 2020; 43: 219-227.
https://doi.org/10.1097/MRR.0000000000000411 DOI: https://doi.org/10.1097/MRR.0000000000000411
Rahimzadeh P, Imani F, Faiz SHR, Entezary SR, Nasiri AA, Ziaeefard M. Investigation the efficacy of intra-articular prolotherapy with erythropoietin and dextrose and intra-articular pulsed radiofrequency on pain level reduction and range of motion improvement in primary osteoarthritis of knee. J Res Med Sci 2014; 19: 696-702.
Reeves KD, Hassanein K. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Altern Ther Health Med 2000; 6: 68-80.
https://doi.org/10.1089/10755530050120673
Reeves KD, Hassanein K. Randomized, prospective, placebo-controlled double-blind study of dextrose prolotherapy for osteoarthritic thumb and finger (DIP, PIP, and trapeziometacarpal) joints: evidence of clinical efficacy. J Altern Complement Med 2000; 6: 311-320.
https://doi.org/10.1089/10755530050120673 DOI: https://doi.org/10.1089/10755530050120673
Sit RWS, Wu RWK, Rabago D, Reeves KD, Chan DCC, Yip BHK, et al. Efficacy of intra-articular hypertonic dextrose (Prolotherapy) for knee osteoarthritis: a randomized controlled trial. Ann Fam Med 2020; 18: 235-242.
https://doi.org/10.1370/afm.2520 DOI: https://doi.org/10.1370/afm.2520
Jahangiri A, Moghaddam FR, Najafi S. Hypertonic dextrose versus corticosteroid local injection for the treatment of osteoarthritis in the first carpometacarpal joint: a double-blind randomized clinical trial. J Orthop Sci 2014; 19: 737-743.
https://doi.org/10.1007/s00776-014-0587-2 DOI: https://doi.org/10.1007/s00776-014-0587-2
Rabago D, Slattengren A, Zgierska A. Prolotherapy in primary care practice. Prim Care 2010; 37: 65-80.
https://doi.org/10.1016/j.pop.2009.09.013 DOI: https://doi.org/10.1016/j.pop.2009.09.013
Dean Reeves K, Fullerton BD, Topol G. Evidence-based regenerative injection therapy (prolotherapy) in sports medicine. Sport Med Resour Man 2008: p. 611-619.
https://doi.org/10.1016/B978-141603197-0.10049-7 DOI: https://doi.org/10.1016/B978-141603197-0.10049-7
Topol GA, Podesta LA, Reeves KD, Giraldo MM, Johnson LL, Grasso R, et al. Chondrogenic effect of intra-articular hypertonic-dextrose (prolotherapy) in severe knee osteoarthritis. PM R 2016; 8: 1072-1082.
https://doi.org/10.1016/j.pmrj.2016.03.008 DOI: https://doi.org/10.1016/j.pmrj.2016.03.008
Distel LM, Best TM. Prolotherapy: a clinical review of its role in treating chronic musculoskeletal pain. PMRJ 2018; 3: S78-S81.
https://doi.org/10.1016/j.pmrj.2011.04.003 DOI: https://doi.org/10.1016/j.pmrj.2011.04.003
Rhatomy S, Margaretha E, Rahmadian R. Dextrose prolotherapy for muscle, tendon and ligament injury or pathology: a systematic review. Annu Res Rev Biol 2020: p. 43-62.
https://doi.org/10.9734/arrb/2020/v35i1030288 DOI: https://doi.org/10.9734/arrb/2020/v35i1030288
Published
How to Cite
License
Copyright (c) 2023 Yose Waluyo, Sari Rajwani Artika, Insani Nanda Wahyuni, Andi Muh Aunul Khaliq Gunawan, Ahmad Taufik Fadillah Zainal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
